BCG isn’t nearly as protective as modern vaccines aim to be. The GSK vaccine in question in the article and similar ones in development in other research groups are aiming to improve protection over BCG.
It’s insane how common latent TB is on a global scale and it’s quite a challenging problem to solve from a technical standpoint.